Login
Lupa
First page / Show document

Show document Help

A- | A+ | Print
Title:Ekonomska analiza stroškovne učinkovitosti natalizumaba pri zdravljenju multiple skleroze (semi markovski pristop)
Authors:ID Mrkaić, Mićo (Author)
ID Pezdir, Rado (Author)
Files:URL http://www.ivz.si/javne_datoteke/bilten/datoteke/133-Mrkaic.pdf
 
Language:Slovenian
Work type:Not categorized
Typology:1.02 - Review Article
Organization:UPR - University of Primorska
Abstract:Multipla skleroza je kronična vnetna bolezen osrednjega živčnega sistema. Praviloma se začne pri mladih odraslih ljudeh in lahko v številnih primerih privede do invalidnosti in nezmožnosti za delo. Vzroki multiple skleroze niso poznani, utemeljeno pa sklepamo, da gre za kombinacijo genetskih in okoljskih dejavnikov. Čeprav zdravila za multiplo sklerozo ni, pa obstajajo zdravila, kispremenijo potek bolezni in upočasnijo njeno napredovanje ter zmanjšajo njene posledice. Zdravila, ki spreminjajo potek bolezni (po angleško disease modifying drugs ali kratko DMD), nosijo s sabo pri svoji uporabi tako stroške kot koristi: stroški so seveda v njihovi nabavi ter v uporabi, ki zahteva strokovne storitve, koristi pa so v manjši pogostosti zagonov bolezni in zmanjševanju prizadetosti obolelih. Cilj te analize je izračunati stroške in koristi uporabe teh zdravil. Za vrednotenje uporabimo semi markovski model napredovanja bolezni po lestvici invalidnosti. V analizi smo naredili oceno skupnih stroškov zmanjšane produktivnosti bolnikov z multiplo sklerozo na eno leto in skozi življenjski cikel. Izkazalo se je, da znašajo povprečni stroški zagonov 1100 evrov letno na bolnika, da so celotni povprečni stroški (upoštevajoč tudi invalidnost) približno 6900 evrov na bolnika. Zdravljenje z zdravilom natalizumab pomembno zniža stroške bolezni: stroške zagonov za 62 % in stroške dolgoročne invalidnosti za približno polovico.
Keywords:multipla skleroza, stroški zdravljenja, zagoni bolezni, koristi zdravljenja, interferoni, nalalizumab
Year of publishing:2009
Number of pages:str. 5-11
Numbering:Letn. 25, št. 1
PID:20.500.12556/RUP-1176 This link opens in a new window
ISSN:1318-2927
UDC:615
COBISS.SI-ID:1024061268 This link opens in a new window
Publication date in RUP:15.10.2013
Views:6386
Downloads:108
Metadata:XML DC-XML DC-RDF
:
MRKAIĆ, Mićo and PEZDIR, Rado, 2009, Ekonomska analiza stroškovne učinkovitosti natalizumaba pri zdravljenju multiple skleroze (semi markovski pristop). [online]. 2009. Vol. 25, no. 1, p. 5–11. [Accessed 8 April 2025]. Retrieved from: http://www.ivz.si/javne_datoteke/bilten/datoteke/133-Mrkaic.pdf
Copy citation
  
Average score:
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
(0 votes)
Your score:Voting is allowed only for logged in users.
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Secondary language

Language:Unknown
Abstract:Multiple sclerosis is a chronic progressive illness of the central nervous system. It is usually first diagnosed in young adults and in many cases leads to disability and early retirement. The cause of the disease is not known, butit is reasonable to suspect both genetic and environmental factors. Despitethe fact that there is not cure for the disease, there exist disease modifying drugs (DMD) which slow the progression of the disease and reduce thedisability caused by it. The use of DMDs carries both costs and benefits: the cost of use and accompanying care and the benefit of less disability, improved quality of life and increased productivity. The goal of this analysisis to evaluate both costs and benefits in the case of Slovenia. We usea semi Markov model of disease progression. The analysis calculates the total cost of lost productivity in Slovene multiple sclerosis patients per year and per life cycle. The average annual cost due to relapses is 1100 eurosand the total average annual cost is 6900 euros. Treatment with natalizumab significantly reduces both costs, the cost of relapses by 62 percent and the cost of long term disability by approximately 50 percent.
Keywords:multiple sclerosis, the cost of care, relapses, therapeutic benefit, interferon, nalalizumab


Comments

Leave comment

You must log in to leave a comment.

Comments (0)
0 - 0 / 0
 
There are no comments!

Back
Logos of partners University of Maribor University of Ljubljana University of Primorska University of Nova Gorica